Bio-Rad Laboratories (BIO) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $2.65
- Estimate
- $2.23
- Surprise
- +19.1%
- Revenue (period 2026-09-30)
- $656.4M
- Score at report (before → after)
- 4.7 → 5.3/10
Revenue source: xbrl.
How the report landed
Bio-Rad Laboratories (BIO) beat the $2.23 estimate with adjusted EPS of $2.65 — a large 19.1% upside surprise. TrendMatrix's engine moved from Sell (4.7/10) to Hold at 5.3/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates BIO Hold at 5.3/10.
2 of the last 4 quarters beat the estimate; this quarter's +19.1% surprise compares with a +14.4% four-quarter average. Next scheduled report: 2027-02-11.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Positive news sentiment (+1.00)
What argues against it
- Earnings expected to decline ~74% (cyclical peak)
- Analyst target reached - limited upside remaining
- Near 52-week high (3.5% away)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $382.53
- Stop
- $355.75
Forward estimates sit below the trailing run-rate (37.9× forward vs 9.8× trailing) — consensus expects earnings to decline from here.
Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.
BIO at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $9.88B
- P/E (fwd)
- 37.9
- P/E (ttm)
- 9.8
- 52-week range
- $236.73–$396.23
- Off 52-week high
- 3.5%
- RSI (14)
- 67
- Volume vs avg
- 0.28×
- Score today
- 5.3/10